Biological and clinical heterogeneity of MYCN-amplified medulloblastoma

Acta Neuropathologica

Volumn 123, Issue 4, 2012, Pages 515-527

  Korshunov, Andrey ^a,b   Remke, Marc ^a,b   Kool, Marcel ^b   Hielscher, Thomas ^b   Northcott, Paul A ^c   Williamson, Dan ^d   Pfaff, Elke ^b   Witt, Hendrik ^a,b   Jones, David T W ^b   Ryzhova, Marina ^e   Cho, Yoon Jae ^f   Wittmann, Andrea ^b   Benner, Axel ^b   Weiss, William A ^g   Von Deimling, Andreas ^a,b   Scheurlen, Wolfram ^h   Kulozik, Andreas E ^a   Clifford, Steven C ^d   Collins, V Peter ⁱ   Westermann, Frank ^b   Taylor, Michael D ^c   Lichter, Peter ^b   Pfister, Stefan M ^a,j   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF TORONTO   (Canada)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Cnopf'Sche Kinderklinik Nü Rnberg Children's Hospital   (Germany)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j Im Neuenheimer Feld 280   (Germany)

more..

Author keywords

10q loss; Medulloblastoma; MYCN; SHH pathway

Indexed keywords

SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI2;

ARTICLE; CANCER PROGNOSIS; CHILD; CHROMOSOME 10; CHROMOSOME 17Q; CHROMOSOME 7Q; CHROMOSOME DELETION; CHROMOSOME DELETION 9Q; CHROMOSOME GAIN; CHROMOSOMES AND CHROMOSOMAL PHENOMENA; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GLI2 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOCHROMOSOME; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MUTATIONAL ANALYSIS; ONCOGENE MYC; ONCOGENE MYCN; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TRANSCRIPTOMICS;

BETA CATENIN; CEREBELLAR NEOPLASMS; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 10; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HEDGEHOG PROTEINS; HUMANS; LONGITUDINAL STUDIES; MALE; MEDULLOBLASTOMA; MICROARRAY ANALYSIS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862278147     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-011-0918-8     Document Type: Article

References (48)

1. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE (2002) MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 126(5):540-544 (Pubitemid 34477948)
2. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O, Macdonald TJ, Albanese C, Toretsky JA, Uren A (2011) Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest 121(1):148-160. doi:10.1172/JCI4287442874
3. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA (2002) Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297(5586):1559-1561. doi: 10.1126/science.1073733297/5586/1559 (Pubitemid 34971004)
4. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson ADJ, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Nicholson J, Bernheim A, Betts DR, Vandesompele J, Van Roy N, Speleman F (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340(25):1954-1961. doi:10.1056/NEJM199906 243402504 (Pubitemid 29288271)
5. Brunet JP, Tamayo P, Golub TR, Mesirov JP (2004) Metagenes and molecular pattern discovery using matrix factorization. ProcNatl Acad Sci USA 101(12):4164-4169. doi:10.1073/pnas. 03085311010308531101 (Pubitemid 38405900)
6. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, Pomeroy SL (2011) Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29(11):1424-1430. doi:10.1200/JCO.2010.28.5148
7. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Dang CV, Burger PC (2004) Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63(5):441-449 (Pubitemid 38669665)
8. Eberhart CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, Burger PC (2002) Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 12(1):36-44 (Pubitemid 33131360)
9. Ellison D (2002) Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 28(4):257-282. doi:10.1046/j.1365-2990.2002.00419.x (Pubitemid 34989289)
10. Ellison DW (2010) Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathol 120(3):305-316. doi:10.1007/s00401-010-0726-6
11. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121(3):381-396. doi: 10.1007/s00401-011-0800-8
12. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, Zhao W, Nicholson SL, Taylor RE, Bailey S, Clifford SC (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29(11):1400-1407. doi:10.1200/ JCO.2010.30.2810
13. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ (2004) Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22(6):984-993. doi:10.1200/JCO.2004.06.032 (Pubitemid 41095029)
14. Goeman JJ, le Cessie S (2006)Agoodness-of-fit test for multinomial logistic regression. Biometrics 62(4):980-985. doi:10.1111/j. 1541-0420.2006.00581.x
15. Graf E, Schmoor C, Sauerbrei W, Schumacher M (1999) Assessment and comparison of prognostic classification schemes for survival data. Stat Med 18(17-18):2529-2545. doi: 10.1002/(SICI)1097-0258(19990915/30)18:17/18\2529 (Pubitemid 29423514)
16. Grotzer MA, von Hoff K, von Bueren AO, Shalaby T, Hartmann W, Warmuth-Metz M, Emser A, Kortmann RD, Kuehl J, Pietsch T, Rutkowski S (2007) Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91-implications for investigating childhood medulloblastoma. Klin Padiatr 219(6):312-317. doi:10.1055/s-2007-985843 (Pubitemid 350244522)
17. Katoh Y, Katoh M (2009) Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 9(7):873-886
18. Kenney AM, Cole MD, Rowitch DH (2003) Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 130(1):15-28 (Pubitemid 36113940)
19. Kessler JD, Hasegawa H, Brun SN, Emmenegger BA, Yang ZJ, Dutton JW, Wang F, Wechsler-Reya RJ (2009) N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes Dev 23(2):157-170. doi:10.1101/gad.1759909
20. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsic A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3(8):e3088. doi:10.1371/journal.pone.0003088
21. Korshunov A, Benner A, Remke M, Lichter P, von Deimling A, Pfister S (2008) Accumulation of genomic aberrations during clinical progression of medulloblastoma. Acta Neuropathol 116(4):383-390. doi:10.1007/s00401-008-0422-y
22. Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Schottler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik AE, von Deimling A, Lichter P, Pfister SM (2010) Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 28(18):3054-3060. doi: 10.1200/JCO.2009.25.7121
23. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW (2004) Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10(16):5482-5493. doi:10.1158/1078- 0432.CCR-03-072110/16/ 5482 (Pubitemid 39100486)
24. Li T, Ding C (2006) The relationships among various nonnegative matrix factorization methods for clustering. Paper presented at the Proceedings of Sixth International Conference on Data Mining
25. Low JA, de Sauvage FJ (2010) Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 28(36):5321-5326. doi:10.1200/JCO.2010.27.9943
26. Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R, Califano A (2006) ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 7(Suppl 1):S7. doi:10.1186/ 1471-2105-7-S1-S7
27. Margolin AA, Wang K, Lim WK, Kustagi M, Nemenman I, Califano A (2006) Reverse engineering cellular networks. Nat Protoc 1(2):662-671. doi:10.1038/nprot.2006.106
28. Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL (2011) Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog 50(6):403-411. doi:10.1002/mc. 20722
29. Northcott PA, Fernandez LA, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, Grundy R, Van Meter T, Rutka JT, Croce CM, Kenney AM, Taylor MD (2009) The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69(8):3249-3255. doi:10.1158/0008-5472.CAN-08-4710
30. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11):1408-1414. doi: 10.1200/JCO.2009.27.4324
31. Northcott PA, Rutka JT, Taylor MD (2010) Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. Neurosurg Focus 28(1):E6. doi:10.3171/ 2009.10.FOCUS09218
32. Oliver TG, Grasfeder LL, Carroll AL, Kaiser C, Gillingham CL, Lin SM, Wickramasinghe R, Scott MP, Wechsler-Reya RJ (2003) Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci USA 100(12):7331-7336. doi:10.1073/ pnas.08323171000832317100 (Pubitemid 36706438)
33. Pession A, Tonelli R (2005) The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr Cancer Drug Targets 5(4):273-283 (Pubitemid 40910560)
34. Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schottler A, Jorch N, Graf N, Kulozik AE, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor MD, Tabori U, Lichter P, Korshunov A, Pfister SM (2010) TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 28(35):5188-5196. doi:10.1200/ JCO.2010.31.1670
35. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A (2009) Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27(10):1627-1636. doi:10.1200/JCO.2008.17.9432
36. Pfister SM, Korshunov A, Kool M, Hasselblatt M, Eberhart C, Taylor MD (2010) Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol 120(5):553-566. doi:10.1007/s00401-010-0751-5
37. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415(6870):436-442. doi:10.1038/415436a (Pubitemid 34100955)
38. Qi Q, Zhao Y, Li M, Simon R (2009) Non-negative matrix factorization of gene expression profiles: a plug-in for BRBArrayTools. Bioinformatics 25(4):545-547. doi:10.1093/bioinfor matics/btp009
39. Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schottler A, von Bueren AO, von Deimling A, Rutkowski S, Scheurlen W, Kulozik AE, Taylor MD, Lichter P, Pfister SM (2011) FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol 29(29):3852-3861. doi:10.1200/JCO.2011.36.2798
40. Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A, Benner A, von Deimling A, Scheurlen W, Perry A, Croul S, Kulozik AE, Lichter P, Taylor MD, Pfister SM, Korshunov A (2011) Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 29(19):2717-2723. doi:10.1200/ JCO.2011.34.9373
41. Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, Warmuth-Metz M, Soerensen N, Emser A, Bode U, Mittler U, Urban C, Benesch M, Kortmann RD, Schlegel PG, Kuehl J, Pietsch T, Grotzer M (2007) Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 13(9):2651-2657. doi:10.1158/1078-0432.CCR-06-1779 (Pubitemid 46788032)
42. Schwab M, Westermann F, Hero B, Berthold F (2003) Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 4(8):472-480 (S1470204503011665[pii]) (Pubitemid 37009955)
43. Scott DK, Straughton D, Cole M, Bailey S, Ellison DW, Clifford SC (2006) Identification and analysis of tumor suppressor loci at chromosome 10q23.3-10q25.3 in medulloblastoma. Cell Cycle 5(20):2381-2389 (3360[pii]) (Pubitemid 44785848)
44. Suzuki R, Shimodaira H (2006) Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22(12):1540-1542. doi:10.1093/bioinformatics/btl117 (Pubitemid 43985330)
45. Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, Jenkins RB, Tihan T, Vandenberg SR, James CD, Tanaka K, Taylor MD, Weiss WA, Chesler L (2010) Pleiotropic role for MYCN in medulloblastoma. Genes Dev 24(10):1059-1072. doi:10.1101/gad.1907510
46. Taylor RE, Bailey CC, Robinson KJ, Weston CL, Walker DA, Ellison D, Ironside J, Pizer BL, Lashford LS (2005) Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41(5):727-734. doi:10.1016/j.ejca.2004.12.017 (Pubitemid 40342556)
47. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, Konig R, Fischer M, Schwab M (2008) Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9(10):R150. doi:10.1186/gb-2008-9-10-r150
48. Zitterbart K, Filkova H, Tomasikova L, Necesalova E, Zambo I, Kantorova D, Slamova I, Vranova V, Zezulkova D, Pesakova M, Pavelka Z, Veselska R, Kuglik P, Sterba J (2010) Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma. J Neurooncol 102:25-33. doi:10.1007/s11060-010-0289-3